Search Results for "michigan"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for michigan. Results 71 to 80 of 308 total matches.

Formoterol (Perforomist) for COPD

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2007  (Issue 1274)
University School of Medicine EDITORIAL FELLOWS: Vanessa K. Dalton, M.D., M.P.H., University of Michigan ...
Formoterol fumarate (Perforomist - Dey), a long-acting beta2-agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of bronchoconstriction associated with chronic obstructive pulmonary disease (COPD). Arformoterol (Brovana), the (R, R)-enantiomer of formoterol, was approved earlier this year for the same indication.
Med Lett Drugs Ther. 2007 Nov 19;49(1274):94-5 |  Show IntroductionHide Introduction

Tdap, DTaP Mix-Ups

   
The Medical Letter on Drugs and Therapeutics • Jan 15, 2007  (Issue 1252)
., University of Michigan Medical School Eric J. Epstein, M.D., Albert Einstein College of Medicine DRUG ...
Medical Letter consultants have brought to our attention some confusion that has accompanied the release of Adacel, a combination of tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap) recently approved for use as a booster in adolescents and adults 11-64 years old (Med Lett Drugs Ther 2006; 48:5). Another Tdap vaccine, Boostrix, is approved for use in adolescents 10-18 years old. Some adults have inadvertently been immunized with Daptacel or Infanrix (DTaP), which are intended for active immunization of infants and children 6 weeks to 6 years old. Such mix-ups were...
Med Lett Drugs Ther. 2007 Jan 15;49(1252):8 |  Show IntroductionHide Introduction

Clarification: Hand Hygiene and CDAD

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 2007  (Issue 1253)
of Michigan Medical School Eric J. Epstein, M.D., Albert Einstein College of Medicine DRUG INTERACTIONS ...
In the recent Medical Letter article on the treatment of Clostridium difficile–associated disease (CDAD) we wrote: “Healthcare workers caring for patients with C. difficile infection should follow contact isolation precautions, especially use of gloves and hand washing with soap and water after glove removal. Alcohol-based products such as hand sanitizers will not eradicate C. difficile spores.”1 One reader pointed out that alcoholbased products do eradicate some C. difficile spores and have been invaluable against other pathogens.In an unpublished study available as an abstract, both...
Med Lett Drugs Ther. 2007 Jan 29;49(1253):9 |  Show IntroductionHide Introduction

In Brief: Toxicity of Gadolinium-Based Contrast Agents

   
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007  (Issue 1262)
. Dalton, M.D., M.P.H., University of Michigan Medical School Eric J. Epstein, M.D., Albert Einstein ...
Gadolinium-based contrast agents, which are used mainly for magnetic resonance imaging and angiography, were first introduced partly because of the discovery in the 1990’s that iodine-based contrast agents could cause nephrotoxicity and acute renal failure. Some recent reports have suggested, however, that gadolinium-based agents may also be nephrotoxic.1 One patient who developed acute renal failure after use of gadolinium-based contrast had a renal biopsy that showed acute tubular injury.2Moreover, after exposure to gadolinium-based contrast, some patients with severe renal insufficiency,...
Med Lett Drugs Ther. 2007 Jun 4;49(1262):45 |  Show IntroductionHide Introduction

Addendum: Warfarin-Acetaminophen Interaction

   
The Medical Letter on Drugs and Therapeutics • Jun 16, 2008  (Issue 1288)
of Michigan Medical School Lauren K. Schwartz, M.D., Mount Sinai School of Medicine PRODUCTION COORDINATOR ...
A reader expressed disappointment that our recent listing of “Some Warfarin Drug Interactions”1 did not include acetaminophen. Perhaps it should have. Acetaminophen can increase the anticoagulant effect of warfarin, particularly with continued use, but it does so inconsistently. The mechanism of this interaction has not been established, but may be related to an acetaminophen metabolite inhibiting vitamin K-epoxide reductase, the target for warfarin’s anticoagulant effect.2Patient susceptibility varies, possibly on a genetic basis; occasional use of acetaminophen generally has little or...
Med Lett Drugs Ther. 2008 Jun 16;50(1288):45 |  Show IntroductionHide Introduction

In Brief: Melamine

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008  (Issue 1297)
K. Dalton, M.D., M.P.H., University of Michigan Medical School Eric J. Epstein, M.D. Albert ...
Melamine present in infant formula and other milk products has been associated with widespread illness and some deaths among infants in China. It was also identified in pet food sold in North America after a large number of pets became ill and some died. In both the infants and the pets, renal injury appeared to be the cause.1Melamine (C3H6N6) is a heterocyclic compound, two-thirds nitrogen by weight, that is slightly soluble in water. When combined with formaldehyde, it forms melamine resin, which has a wide variety of industrial applications including the manufacturing of kitchenware,...
Med Lett Drugs Ther. 2008 Oct 20;50(1297):81 |  Show IntroductionHide Introduction

In Brief: New Propellants for Albuterol Metered-Dose Inhalers

   
The Medical Letter on Drugs and Therapeutics • Nov 03, 2008  (Issue 1298)
, Pharm.D. CONTRIBUTING EDITORS: Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School ...
Inhaled drugs for asthma are available in the US mainly in pressurized metered-dose inhalers (MDIs), which require a propellant, and dry powder inhalers, which do not. The chlorofluorocarbon (CFC) propellants in MDIs are being replaced by hydrofluoroalkane (HFA) propellants for environmental reasons: CFCs contribute to the depletion of the ozone layer. December 31, 2008 will be the last day that albuterol MDIs using CFC propellants can be sold in the US. The FDA is expected to announce a termination date for other CFC-containing products in the near future.Three HFA albuterol inhalers and one...
Med Lett Drugs Ther. 2008 Nov 3;50(1298):85 |  Show IntroductionHide Introduction

In Brief: Fluoroquinolones and Tendon Injuries

   
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008  (Issue 1300)
, Pharm.D. CONTRIBUTING EDITORS: Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School ...
The FDA has added a boxed warning to fluoroquinolone package inserts about tendon injuries that may occur as a result of their use. Tendinitis or tendon rupture may occur rarely with systemic use of any fluoroquinolone, either while the drug is being taken or for up to several months afterwards.Fluoroquinolone-related tendon injury is rare; estimates for its incidence in the general population range from 0.14% to 0.4%. The risk is higher for patients >60 years old and for those taking corticosteroids. For patients with organ transplants, the incidence may be as high as 15%.1 A case-control...
Med Lett Drugs Ther. 2008 Dec 1;50(1300):93 |  Show IntroductionHide Introduction

In Brief: Different Diets

   
The Medical Letter on Drugs and Therapeutics • Mar 23, 2009  (Issue 1308)
and Surgeons Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School Eric J. Epstein, M.D ...
A recent article in the New England Journal of Medicine confirms something that others, including The Medical Letter (Treat Guidel Med Lett 2008; 6:23), have been saying for years: no particular combination of protein, carbohydrate and fat in the diet offers any advantage in losing weight. This randomized 2-year trial followed 800 overweight and obese subjects on low fat/average protein, low fat/high protein, high fat/average protein, and high fat/high protein diets. Carbohydrate intake varied from 35% (in the high fat/high protein diet) to 65% (in the low fat/average protein diet). All...
Med Lett Drugs Ther. 2009 Mar 23;51(1308):24 |  Show IntroductionHide Introduction

In Brief: Plan B for 17-Year Olds

   
The Medical Letter on Drugs and Therapeutics • May 18, 2009  (Issue 1312)
. Dalton, M.D., M.P.H., University of Michigan Medical School Eric J. Epstein, M.D. Albert Einstein ...
The FDA has announced that it will lower the age for over-the-counter access to the emergency contraceptive Plan B1 from 18 to 17 years old. In a randomized, controlled trial, the two 0.75-mg levonorgestrel tablets in Plan B, taken 12 hours apart beginning within 72 hours after unprotected intercourse, decreased the overall pregnancy rate to 1.1% (11/976) of women who requested emergency contraception.2 The sooner the drug is taken after coitus, the more effective it is. Nausea and vomiting can occur with Plan B. Fetal malformations have not been associated with pregnancies that occurred...
Med Lett Drugs Ther. 2009 May 18;51(1312):40 |  Show IntroductionHide Introduction